ArticleDiagnostic cytopathology2026
Application of Sydney System for Lymph Node Cytology at a Tertiary Care Centre in Central India.
Article in Diagnostic cytopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of Sydney System for Lymph Node Cytology at a Tertiary Care Centre in Central India.Diagnostic cytopathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFine-needle aspiration cytology (FNAC) of a lymph node has become a reliable and well-accepted first-level diagnostic technique due to its minimally invasive nature, rapid turnaround time, and low cost. The lack of standard guidelines and the question of how it can provide diagnostic information have reduced its acceptance. The Sydney system for lymph node cytology provides a comprehensive standardized approach to lymph node FNA. In our study, we have introduced the Sydney system for performance, classification, and reporting of lymph node FNAC at a tertiary care center and correlated it with the histopathological diagnosis wherever available. MATERIALS AND
methodsAll lymph node aspiration done at our institute from January 2014 to April 2023 (n = 647) with and without histopathological reports were obtained and the Sydney category was assigned accordingly. The study was ambispective. The retrospective cases (n = 471) were reclassified according to the Sydney system and 176 cases were performed and reported as per the Sydney system.
resultsIn the present study, 647 LN FNAC cases were included and categorized according to the Sydney system of reporting LN FNAC. Among them, 46/647 (7.1%) cases were categorized into the Inadequate category, 367/647 (56.7%) into the Benign category, 23/647 (3.5%) cases into the Atypia of undetermined significance/Atypical lymphoid cells of undetermined significance category, 36/647 (5.5%) cases into the Suspicious of Malignancy category, and 175/647 (27%) cases into the Malignant category. One hundred and thirty-six cases were histopathologically examined. The sensitivity, specificity, PPV, NPV, and diagnostic accuracy in these categories were 98.7%, 97.9%, 98.7%, 97.9%, and 98.4%. Risk of malignancy (ROM) was 100% in Category I, 2.1% in Category II, 75% in Category III, 95.4% in Category IV, and 100% in Category V.
conclusionAdoption of the Sydney system, by the introduction of standardized categorization, may improve the LN FNAC diagnostic accuracy. The tiered risk stratification classification scheme, as proposed by the Sydney system, may prove helpful in risk stratification and effectively guiding the clinical management of patients with lymphadenopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.